Neuraxis (NRXS) Receivables (2022 - 2026)
Neuraxis (NRXS) posted Receivables of $913808.0 for Q1 2026, up 2.86% sequentially from $888386.0 in Q4 2025, and up 106.35% YoY from $442853.0 in Q1 2025.
Neuraxis (NRXS) Receivables (2022 - 2026) Analysis & Trends
Neuraxis has reported Receivables for 5 years, with the latest figure at $913808.0 in Q1 2026.
- Quarterly Receivables rose 106.35% year-over-year to $913808.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $913808.0 (up 106.35% YoY) and the FY2025 annual result came in at $888386.0, up 162.08% from the prior year.
- Receivables improved to $913808.0 in Q1 2026 per NRXS's latest filing, from $888386.0 in the prior quarter.
- Over five years, Receivables peaked at $913808.0 in Q1 2026 and troughed at $94920.0 in Q4 2023.
- A 5-year average of $390112.2 and a median of $244163.0 in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2025: Receivables slumped 64.64% in 2023, then surged 315.2% in 2025.
- Over 5 years, Receivables stood at $268406.0 in 2022, then plunged by 64.64% to $94920.0 in 2023, then surged by 125.42% to $213967.0 in 2024, then soared by 315.2% to $888386.0 in 2025, then gained by 2.86% to $913808.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $913808.0, $888386.0, and $671004.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | 791,900.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 791,900.00 |
| Mar 31, 2026 | 913,808.00 |
| Dec 31, 2025 | 888,386.00 |
| Sep 30, 2025 | 671,004.00 |
| Jun 30, 2025 | 503,518.00 |
| Mar 31, 2025 | 442,853.00 |
| Dec 31, 2024 | 213,967.00 |
| Sep 30, 2024 | 230,708.00 |
| Jun 30, 2024 | 230,173.00 |
| Mar 31, 2024 | 244,163.00 |
| Dec 31, 2023 | 94,920.00 |
| Sep 30, 2023 | 132,382.00 |
| Jun 30, 2023 | 237,170.00 |
| Dec 31, 2022 | 268,406.00 |